Olema Pharmaceuticals, Inc. — Form 8-K Summary
Reporting event: Annual meeting of stockholders held June 16, 2022; the Form 8-K was signed and dated June 23, 2022. Olema Pharmaceuticals is a Delaware corporation whose common stock trades on Nasdaq under the symbol OLMA.
Business Context and Reporting Period
This filing reports the results of the company’s 2022 annual meeting of stockholders under Item 5.07. It does not provide operating or financial results for a quarterly or annual reporting period.
Financial and Operating Metrics
The filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, cash balances, research and development spending, or other financial metrics.
Material Changes and Meeting Results
| Proposal | Result | Vote details |
|---|---|---|
| Election of directors | All three Class II nominees elected to serve until the 2025 annual meeting and until successors are elected and qualified. | Cynthia Butitta: 25,158,671 for; Cyrus Harmon, Ph.D.: 24,729,582 for; Graham Walmsley, M.D., Ph.D.: 25,116,924 for. Each nominee had 2,442,960 broker non-votes. |
| Advisory vote on executive compensation | Approved on an advisory basis. | 21,851,764 for; 3,812,824 against; 1,922,018 abstentions; 2,442,960 broker non-votes. |
| Frequency of advisory compensation votes | Stockholders preferred annual voting. | 25,259,988 for one year; 1,746 for two years; 411,608 for three years; 1,913,265 abstentions. |
| Independent registered public accounting firm | Ernst & Young LLP ratified for the year ending December 31, 2022. | 28,072,697 for; 26,193 against; 1,930,677 abstentions. |
Guidance, Outlook, Risks and Unusual Items
The company stated that it will include a non-binding advisory vote on named executive officer compensation in its proxy materials every year, consistent with the stockholder vote and board recommendation. Such frequency votes are required every six calendar years. The filing provides no financial guidance, operating outlook, risk disclosures, contingencies, or unusual financial items.
Key Facts for Investors to Verify
- Confirm the election and continuing terms of the three Class II directors.
- Review the executive compensation proposal and the company’s annual say-on-pay commitment.
- Confirm Ernst & Young LLP as the independent registered public accounting firm for 2022.
- Consult the April 28, 2022 definitive proxy statement for detailed proposal and compensation information.
- Use the company’s periodic reports, rather than this 8-K, to assess financial performance, liquidity, cash runway, indebtedness, and clinical or operating risks.